However, the intensity of LATS1 immunoreactivity varied between cancer cells since it was absent or weak in 22/54 (40.7%) and moderate to strong in 32/54 (59.3%) of ccRCC patients. This evidence concerns the gene LATS1 and nonpapillary renal cell carcinoma.